AR044336A1 - Tratamientos de ansiedad con ziprasidona - Google Patents
Tratamientos de ansiedad con ziprasidonaInfo
- Publication number
- AR044336A1 AR044336A1 ARP040101651A ARP040101651A AR044336A1 AR 044336 A1 AR044336 A1 AR 044336A1 AR P040101651 A ARP040101651 A AR P040101651A AR P040101651 A ARP040101651 A AR P040101651A AR 044336 A1 AR044336 A1 AR 044336A1
- Authority
- AR
- Argentina
- Prior art keywords
- optionally substituted
- fluoro
- chloro
- quinolyl
- phenyl
- Prior art date
Links
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 title abstract 3
- 208000019901 Anxiety disease Diseases 0.000 title abstract 2
- 229960000607 ziprasidone Drugs 0.000 title abstract 2
- 230000036506 anxiety Effects 0.000 title 1
- 238000011282 treatment Methods 0.000 title 1
- -1 benzoisothiazolyl Chemical group 0.000 abstract 13
- 125000001153 fluoro group Chemical group F* 0.000 abstract 5
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000002253 acid Substances 0.000 abstract 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 2
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 abstract 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 2
- 125000001041 indolyl group Chemical group 0.000 abstract 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 125000005493 quinolyl group Chemical group 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 abstract 1
- 239000012458 free base Substances 0.000 abstract 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 125000005956 isoquinolyl group Chemical group 0.000 abstract 1
- 125000001624 naphthyl group Chemical group 0.000 abstract 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 abstract 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 abstract 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Indole Compounds (AREA)
Abstract
Reivindicación 1: Un procedimiento de tratamiento de ansiedad situacional en un mamífero en necesidad del mismo que comprende al administración a dicho mamífero de una cantidad farmacéuticamente eficaz de un compuesto de fórmula (1), o una sal de adición de ácido farmacéuticamente aceptable del mismo, en la que Ar es benzoisotiazolilo o un óxido o dióxido del mismo cada uno opcionalmente sustituido con un fluoro, cloro, trifluorometilo, metoxi, ciano, nitro o naftilo opcionalmente sustituido con fluoro, cloro, trifluorometilo, metoxi, ciano o nitro; quinolilo; 6-hidroxi-8-quinolilo; isoquinolilo, quinazolilo; benzotiazolilo; benzotiadiazolilo; benzotriazolilo; benzoxazolilo; benzoxazolonilo; indolilo; indanilo opcionalmente sustituido con uno o dos fluoro, 3-indazolilo opcionalmente sustituido con 1-trifluorometilfenilo; o ftalazinilo; n es 1 ó 2; y X e Y junto con el fenilo al que están unidos forman quinolilo; 2-hidroxiquinolilo; benzotiazolilo; 2-aminobenzotiazolilo; benzoisotiazolilo; indazolilo; 2-hidroxiindazolilo; indolilo; espiro; oxindolilo opcionalmente sustituido con uno a tres de alquilo (C1-3), o uno de cloro, fluoro o fenilo, dicho fenilo opcionalmente sustituido con un cloro o fluoro; benzoxazolilo; 2-aminobenzoxazolilo; benzoxazolonilo; 2-aminobenzoxazolinilo; benzotiazolonilo; benzoimidazolonilo; o benzotriazolilo, o una sal de adición de ácido farmacéuticamente aceptable de los mismos. Reivindicación 7: El procedimiento de cualquier reivindicación precedente en el que el compuesto es la base libre de ziprasidona o una sal de ziprasidona farmacéuticamente aceptable.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US47138303P | 2003-05-16 | 2003-05-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044336A1 true AR044336A1 (es) | 2005-09-07 |
Family
ID=33452444
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101651A AR044336A1 (es) | 2003-05-16 | 2004-05-14 | Tratamientos de ansiedad con ziprasidona |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20050004138A1 (es) |
| EP (1) | EP1633361A1 (es) |
| JP (1) | JP2007522095A (es) |
| AR (1) | AR044336A1 (es) |
| BR (1) | BRPI0410419A (es) |
| CA (1) | CA2525868A1 (es) |
| MX (1) | MXPA05012392A (es) |
| TW (1) | TW200427451A (es) |
| WO (1) | WO2004100955A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2323451T7 (es) | 2001-07-20 | 2011-08-01 | Psychogenics Inc. | Tratamiento para el trastorno de hiperactividad con deficit de atencion. |
| MY144968A (en) * | 2005-04-11 | 2011-11-30 | Xenon Pharmaceuticals Inc | Spiro-oxindole compounds and their uses as therapeutic agents |
| AR053710A1 (es) * | 2005-04-11 | 2007-05-16 | Xenon Pharmaceuticals Inc | Compuestos espiroheterociclicos y sus usos como agentes terapeuticos |
| AR056317A1 (es) * | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| CA2635439A1 (en) * | 2006-01-27 | 2007-08-02 | Pfizer Products Inc. | Aminophthalazine derivative compounds |
| AU2007307638A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Spiro (furo [3, 2-C] pyridine-3-3 ' -indol) -2' (1'H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain |
| CA2665698A1 (en) * | 2006-10-12 | 2008-05-22 | Xenon Pharmaceuticals Inc. | Use of spiro-oxindole compounds as therapeutic agents |
| AU2007307635A1 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents |
| EP2334657B1 (en) | 2008-09-22 | 2013-03-06 | F. Hoffmann-La Roche AG | Piperazine d3 and 5-ht2a receptor modulators |
| EP2350091B1 (en) * | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| US8263606B2 (en) | 2008-10-17 | 2012-09-11 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
| AR077252A1 (es) | 2009-06-29 | 2011-08-10 | Xenon Pharmaceuticals Inc | Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos |
| RU2544852C2 (ru) | 2009-10-14 | 2015-03-20 | Ксенон Фармасьютикалз Инк. | Способы синтеза спиро-оксиндольных соединений |
| US20110086899A1 (en) * | 2009-10-14 | 2011-04-14 | Xenon Pharmaceuticals Inc. | Pharmaceutical compositions for oral administration |
| MY165117A (en) | 2010-02-26 | 2018-02-28 | Xenon Pharmaceuticals Inc | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents |
| US8877778B2 (en) | 2010-12-15 | 2014-11-04 | Hoffmann-La Roche Inc. | Benzofurane compounds |
| US8921397B2 (en) | 2011-05-04 | 2014-12-30 | Hoffmann-La Roche Inc. | Benzofurane-piperidine compounds |
| WO2016127068A1 (en) | 2015-02-05 | 2016-08-11 | Teva Pharmaceuticals International Gmbh | Methods of treating postherpetic neuralgia with a topical formulation of a spiro-oxindole compound |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX173362B (es) * | 1987-03-02 | 1994-02-23 | Pfizer | Compuestos de piperazinil heterociclicos y procedimiento para su preparacion |
| US4883795A (en) * | 1988-01-22 | 1989-11-28 | Pfizer Inc. | Piperazinyl-heterocyclic compounds |
| US4831031A (en) * | 1988-01-22 | 1989-05-16 | Pfizer Inc. | Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity |
| ATE236902T1 (de) * | 1996-05-07 | 2003-04-15 | Pfizer | Mesylat des trihydrats des 5-(2-(4-(1,2- benzothiazol-3-yl)-1-piperazinyl)ethyl)-6-chlor 1,3-dihydro-2(1h)-indol-2-ons (=ziprasidon), seine herstellung und seine anwendung als dopamin d2 antagonist |
| ZA977967B (en) * | 1996-09-23 | 1999-03-04 | Lilly Co Eli | Combination therapy for treatment of psychoses |
| IL125951A (en) * | 1997-09-05 | 2003-09-17 | Pfizer Prod Inc | A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal |
| IL127497A (en) * | 1997-12-18 | 2002-07-25 | Pfizer Prod Inc | Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders |
| US6387904B2 (en) * | 1998-05-18 | 2002-05-14 | Pfizer Inc | Method of treating glaucoma and ischemic retinopathy |
| CA2324813A1 (en) * | 1999-11-10 | 2001-05-10 | Susan Beth Sobolov-Jaynes | Combination treatment for depression and anxiety |
| US6572890B2 (en) * | 2000-01-13 | 2003-06-03 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
| AU783516B2 (en) * | 2001-04-30 | 2005-11-03 | Warner-Lambert Company | Methods, kits and compositions for using pyrrole derivatives |
| MXPA05004299A (es) * | 2002-10-25 | 2005-08-03 | Pfizer Prod Inc | Formulacion de liberacion prolongada de agentes activos arilheterociclicos en forma de suspension. |
-
2004
- 2004-05-05 CA CA002525868A patent/CA2525868A1/en not_active Abandoned
- 2004-05-05 WO PCT/IB2004/001561 patent/WO2004100955A1/en active Application Filing
- 2004-05-05 BR BRPI0410419-6A patent/BRPI0410419A/pt not_active IP Right Cessation
- 2004-05-05 JP JP2006530651A patent/JP2007522095A/ja active Pending
- 2004-05-05 MX MXPA05012392A patent/MXPA05012392A/es unknown
- 2004-05-05 EP EP04731229A patent/EP1633361A1/en not_active Withdrawn
- 2004-05-14 US US10/845,824 patent/US20050004138A1/en not_active Abandoned
- 2004-05-14 TW TW093113658A patent/TW200427451A/zh unknown
- 2004-05-14 AR ARP040101651A patent/AR044336A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| BRPI0410419A (pt) | 2006-05-30 |
| CA2525868A1 (en) | 2004-11-25 |
| JP2007522095A (ja) | 2007-08-09 |
| US20050004138A1 (en) | 2005-01-06 |
| EP1633361A1 (en) | 2006-03-15 |
| MXPA05012392A (es) | 2006-02-02 |
| TW200427451A (en) | 2004-12-16 |
| WO2004100955A1 (en) | 2004-11-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044336A1 (es) | Tratamientos de ansiedad con ziprasidona | |
| AR046586A1 (es) | Tratamientos de trastornos bipolares y sintomas asociados | |
| DK0931547T3 (da) | Piperzinylheterocykliske forbindelser til behandlingen af demens | |
| PE20121066A1 (es) | Derivados de diazahomoadamantano y metodos para usarlos | |
| AR110051A2 (es) | Pirazolo[3,4-d]pirimidinas útiles para tratar trastornos respiratorios | |
| AR063015A1 (es) | Derivados de quinazolinona 5-sustituida y composiciones que los comprenden y metodos para utilizarlos en el tratamiento del cancer | |
| AR054799A1 (es) | Derivados de oxindol | |
| KR880011142A (ko) | 피페라지닐-헤테로 시클릭 화합물 | |
| PE20081344A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR047557A1 (es) | Compuestos derivados de piridazina y su uso como agentes terapeuticos | |
| UY29246A1 (es) | Nuevos compuestos | |
| AR060535A1 (es) | Pirido-piridazinonas y ftalazinonas como antagonistas duales de los receptores h1 y h3 de histamina | |
| NO20083032L (no) | Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av mani og bipolar forstyrrelse | |
| AR029805A1 (es) | Compuestos heterociclicos, un proceso para su preparacion , intermediarios, composicion farmaceutica, un proceso para su preparacion, y el uso de dichos compuestos para la fabricacion de un medicamento | |
| DE60206198T2 (de) | Tetrahydrochinolinderivate als muscarinische agonisten | |
| AR068014A1 (es) | Derivados de pirimidin-2-il-amina, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por la inhibicion de la cinasa. | |
| NO20083004L (no) | Anvendelse av benzofuserte heterocykliske sulfamidderivater for behandling av stoffmisbrukavhengighet | |
| EA200801308A1 (ru) | Комбинации, включающие ингибитор cdk и антитело фактора роста, или антимитотик | |
| AR050711A1 (es) | Derivados arilsulfonilestilbeno para el tratamiento y/o prevencion de afecciones del sistema nervioso central | |
| DE60216745D1 (de) | Carbolin Derivate als Hemmstoffe von Phospphodiesterase 5 (PDE5) zur Behandlung kardiovaskulärer Erkrankungen und der erektilen Dysfunktion | |
| UY27798A1 (es) | Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatits c y composiciones y tratamientos que los usan. | |
| BRPI0514724A (pt) | inibidores da enzima hiv integrase | |
| ITTO20050170A1 (it) | Procedimento e dispositivo per l'eliminazione di difetti del filato | |
| AR040472A1 (es) | Derivado de 2-(fenil)-2h-pirazol-3-carboxilico-n-4(tioxo-heterociclil)fenil-amida e imino-heterociclil derivados y compuestos relacionados, procedimiento, medicamentos, kit | |
| AR004970A1 (es) | Sales de derivados de la quinolina, composiciones farmaceuticas que comprenden dichas sales y procedimientos para preparar dichas sales. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |